Division of Palliative Care, University of Toronto, Toronto, ON, Canada.
Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada.
Palliat Med. 2021 Jul;35(7):1295-1322. doi: 10.1177/02692163211015567. Epub 2021 May 17.
Screening for problematic opioid use is increasingly recommended in patients receiving palliative care.
To identify tools used to assess for the presence or risk of problematic opioid use in palliative care.
Scoping review.
Bibliographic databases (inception to January 31, 2020), reference lists, and grey literature were searched to find primary studies reporting on adults receiving palliative care and prescription opioids to manage symptoms from advanced cancer, neurodegenerative diseases, or end-stage organ diseases; and included tools to assess for problematic opioid use. There were no restrictions based on study design, location, or language.
We identified 42 observational studies (total 14,431 participants) published between 2009 and 2020 that used questionnaires ( = 32) and urine drug tests ( = 21) to assess for problematic opioid use in palliative care, primarily in US ( = 38) and outpatient palliative care settings ( = 36). The questionnaires were Cut down, Annoyed, Guilty, and Eye-opener (CAGE, = 8), CAGE-Adapted to Include Drugs (CAGE-AID, = 6), Opioid Risk Tool ( = 9), Screener and Opioid Assessment for Patients with Pain (SOAPP; = 3), SOAPP-Revised ( = 2), and SOAPP-Short Form ( = 5). Only two studies' primary objectives were to evaluate a questionnaire's psychometric properties in patients receiving palliative care. There was wide variation in how urine drug tests were incorporated into palliative care; frequency of abnormal urine drug test results ranged from 8.6% to 70%.
Given the dearth of studies using tools developed or validated specifically for patients receiving palliative care, further research is needed to inform clinical practice and policy regarding problematic opioid use in palliative care.
在接受姑息治疗的患者中,越来越多地建议筛查有问题的阿片类药物使用情况。
确定用于评估姑息治疗中存在或有问题的阿片类药物使用风险的工具。
范围综述。
从各文献数据库(成立至 2020 年 1 月 31 日)、参考文献列表和灰色文献中搜索了报告接受姑息治疗和开处方阿片类药物以缓解晚期癌症、神经退行性疾病或终末期器官疾病引起的症状的成年人的初步研究,并纳入了评估有问题的阿片类药物使用的工具。本研究未基于研究设计、地点或语言进行任何限制。
我们确定了 42 项观察性研究(共有 14431 名参与者),这些研究发表于 2009 年至 2020 年期间,使用问卷( = 32)和尿液药物检测( = 21)来评估姑息治疗中阿片类药物的使用问题,主要在美国( = 38)和门诊姑息治疗环境中( = 36)。问卷包括 Cut down, Annoyed, Guilty, and Eye-opener(CAGE, = 8)、CAGE-Adapted to Include Drugs(CAGE-AID, = 6)、Opioid Risk Tool( = 9)、Screener and Opioid Assessment for Patients with Pain(SOAPP; = 3)、SOAPP-Revised( = 2)和 SOAPP-Short Form( = 5)。只有两项研究的主要目的是评估问卷在接受姑息治疗的患者中的心理测量特性。尿液药物检测在姑息治疗中的应用存在很大差异;异常尿液药物检测结果的频率范围从 8.6%到 70%不等。
鉴于针对接受姑息治疗的患者开发或验证特定工具的研究甚少,因此需要进一步研究,以便为姑息治疗中阿片类药物的使用问题提供临床实践和政策依据。